NCT01643447View on ClinicalTrials.gov

Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

April 30, 2015

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Ulinastatin

Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)

DRUG

Diammonium glycyrrhizinate

Trial Locations (1)

Unknown

Eastern Hepatobiliary Surgery Hospital, Shanghai

All Listed Sponsors
lead

Eastern Hepatobiliary Surgery Hospital

OTHER

NCT01643447 - Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter